Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Острые лимфобластные лейкозы

Список литературы

  1. Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика; 2018: 887–959.
  2. Савченко В.Г., Паровичникова Е.Н. Острые лейкозы // Клиническая онкогематология: руководство для врачей. Под ред. Волковой М.А.. 2-е изд., перераб. и доп. 2007. P. 409–502.
  3. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) / ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.
  4. Brown P.A. et al. NCCN Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia. Version 2.2019. 2019. 115 p.
  5. Gökbuget N. et al. Recommendations of the European Working Group for Adult ALL (EWALL) // UNI-MED Verlag AG. 2011. 204 p.
  6. Румянцев А.Г. Эволюция лечения острого лимфобластного лейкоза у детей: эмпирические, биологические и организационные аспекты // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2015. Vol. 14, № 1. P. 5–15.
  7. Масчан М.А., Мякова Н.В. Острый лимфобластный лейкоз у детей // Вместе против рака. 2006. Vol. 1–2. P. 50–63.
  8. Ахмерзаева З.Х. et al. Эпидемиологическое исследование острых лейкозов в отдельных регионах Российской Федерации // Гематология и трансфузиология. 2014. Vol. 59, № S1. P. 13–14.
  9. Burmeister T. et al. Patients’ age and BCR-ABL frequency in adult B-precursor ALL: A retrospective analysis from the GMALL study group // Blood. 2008. Vol. 112, № 3. P. 918–919.
  10. Rowe J.M. Prognostic factors in adult acute lymphoblastic leukaemia. // Br. J. Haematol. 2010. Vol. 150, № 4. P. 389–405.
  11. Hoelzer D. et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. // Blood. 1988. Vol. 71, № 1. P. 123–131.
  12. Lazarus H.M. et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. // Blood. 2006. Vol. 108, № 2. P. 465–472.
  13. Bassan R., Maino E., Cortelazzo S. Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. // Eur. J. Haematol. 2016. Vol. 96, № 5. P. 447–460.
  14. Cortelazzo S. et al. Lymphoblastic lymphoma. // Crit. Rev. Oncol. Hematol. 2017. Vol. 113. P. 304–317.
  15. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am. J. Clin. Oncol. 1982. Vol. 5, № 6. P. 649–655.
  16. Roila F. et al. Intra and interobserver variability in cancer patients’ performance status assessed according to Karnofsky and ECOG scales // Ann. Oncol. Oxford University Press (OUP), 1991. Vol. 2, № 6. P. 437–439.
  17. Kornberg A., Polliack A. Serum lactic dehydrogenase (LDH) levels in acute leukemia: marked elevations in lymphoblastic leukemia // Blood. 1980. Vol. 56, № 3.
  18. Olgar S. et al. Electrolyte abnormalities at diagnosis of acute lymphocytic leukemia may be a clue for renal damage in long-term period. // J. Pediatr. Hematol. Oncol. 2005. Vol. 27, № 4. P. 202–206.
  19. Ku G.H. et al. Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival // Blood. 2009. Vol. 113, № 17. P. 3911–3917.
  20. Nur S. et al. Disseminated intravascular coagulation in acute leukaemias at first diagnosis. // Eur. J. Haematol. 1995. Vol. 55, № 2. P. 78–82.
  21. Törnebohm E. et al. Bleeding complications and coagulopathy in acute leukaemia. // Leuk. Res. 1992. Vol. 16, № 10. P. 1041–1048.
  22. Галстян Г.М. et al. Тромбогеморрагические осложнения при лечении больных острым лимфобластным лейкозом L-аспарагиназой. // Клиническая онкогематология. 2018. Vol. 11, № 1. P. 89–99.
  23. Coiffier B. et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review // Journal of Clinical Oncology. 2008. Vol. 26, № 16. P. 2767–2778.
  24. Ratner L. et al. Adverse prognostic influence of hepatitis B virus infection in acute lymphoblastic leukemia. // Cancer. 1986. Vol. 58, № 5. P. 1096–1100.
  25. Bianco E. et al. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin’s lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. // Haematologica. 2004. Vol. 89, № 1. P. 70–76.
  26. Zhu R., et al. Intestinal colonization with carbapenem-resistant enterobacteriaceae in acute leukemia patients: risk factors and molecular characteristics. Infect Drug Resist. 2022; 15: 4275-4283.
  27. Приказ Министерства здравоохранения РФ от 20 октября 2020 г. N 1134н "Об утверждении порядка медицинского обследования реципиента, проведения проб на индивидуальную совместимость, включая биологическую пробу, при трансфузии донорской крови и (или) ее компонентов"
  28. Thomas X. et al. Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors. // Leuk. Res. 2002. Vol. 26, № 10. P. 909–918.
  29. Kröber S.M. et al. Acute lymphoblastic leukaemia: Correlation between morphological/immunohistochemical and molecular biological findings in bone marrow biopsy specimens // J. Clin. Pathol. - Mol. Pathol. 2000. Vol. 53, № 2. P. 83–87.
  30. Olsen R.J. et al. Acute leukemia immunohistochemistry: a systematic diagnostic approach. // Arch. Pathol. Lab. Med. 2008. Vol. 132, № 3. P. 462–475.
  31. Bene M.C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). // Leukemia. 1995. Vol. 9, № 10. P. 1783–1786.
  32. McKenna R.W. et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. // Blood. 2001. Vol. 98, № 8. P. 2498–2507.
  33. Moorman A. V et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. // Blood. 2007. Vol. 109, № 8. P. 3189–3197.
  34. Moorman A. V et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. // Blood. 2010. Vol. 115, № 2. P. 206–214.
  35. Yilmaz M. et al. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults: Current Treatments and Future Perspectives // Clinical Advances in Hematology & Oncology. 2018. Vol. 16.
  36. Angi M. et al. The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases // Hematol. Oncol. Stem Cell Ther. King Faisal Specialist Hospital and Research Centre, 2017. Vol. 10, № 3. P. 126–134.
  37. Cimino G. et al. The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience // Haematologica. 2010. Vol. 95, № 5. P. 837–840.
  38. Gazzola A. et al. The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies // Therapeutic Advances in Hematology. 2014. Vol. 5, № 2. P. 35–47.
  39. Thomas X., Le Q.-H. Central nervous system involvement in adult acute lymphoblastic leukemia. // Hematology. 2008. Vol. 13, № 5. P. 293–302.
  40. Aguirre-Guillén W.A. et al. Omics techniques and biobanks to find new biomarkers for the early detection of acute lymphoblastic leukemia in middle-income countries: a perspective from Mexico // Boletin Medico del Hospital Infantil de Mexico. Masson-Doyma Mexico, S.A., 2017. Vol. 74, № 3. P. 227–232.
  41. Herrmann J. et al. Evaluation and management of patients with heart disease and cancer: Cardio-oncology // Mayo Clin. Proc. 2014. Vol. 89, № 9. P. 1287–1306.
  42. Roberts A.S. et al. Extramedullary haematopoiesis: radiological imaging features // Clinical Radiology. 2016. Vol. 71, № 9. P. 807–814.
  43. Soylu A.R. et al. Overt gastrointestinal bleeding in haematologic neoplasms // Dig. Liver Dis. 2005. Vol. 37, № 12. P. 917–922.
  44. Hummel M. et al. Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates. // Ann. Hematol. 2008. Vol. 87, № 4. P. 291–297.
  45. Sengar M. et al. Whole Body PET-CT In Management Of Lymphoblastic Lymphomas In Adults: Does It Have a Prognostic Impact? // Blood. American Society of Hematology, 2013. Vol. 122, № 21. P. 4314–4314.
  46. Khaled S.K., Thomas S.H., Forman S.J. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults // Current Opinion in Oncology. 2012. Vol. 24, № 2. P. 182–190.
  47. Ribera J.M. Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: When and how // Haematologica. 2011. Vol. 96, № 8. P. 1083–1086.
  48. Woitek R. et al. Radiological staging in pregnant patients with cancer // ESMO Open. 2016. Vol. 1, № 1. P. e000017.
  49. Охмат В.А. et al. Инфекционные осложнения у взрослых больных острыми лимфобластными лейкозами на разных этапах химиотерапии по протоколу ОЛЛ-2009. // Онкогематология. 2017. Vol. 12, № 3. P. 31–40.
  50. Biswal S., Godnaik C. Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards // Ecancermedicalscience. ecancer Global Foundation, 2013. Vol. 7, № 1.
  51. Торопова И.Ю. Клинический мониторинг инфекционных осложнений у больных гемобластозами на фоне программной химиотерапии. Диссертация на соискание ученой степени кандидата медицинских наук. 2015. 89 p.
  52. El Fakih R. et al. Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. // Am. J. Hematol. 2018. Vol. 93, № 2. P. 286–295.
  53. Van Dongen J.J.M. et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies // Blood. American Society of Hematology, 2015. Vol. 125, № 26. P. 3996–4009.
  54. van der Velden V.H.J. et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data // Leukemia. Nature Publishing Group, 2007. Vol. 21, № 4. P. 604–611.
  55. Gökbuget N. et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. // Blood. 2012. Vol. 120, № 9. P. 1868–1876.
  56. Kantarjian H. et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia // Cancer. 2004. Vol. 101, № 12. P. 2788–2801.
  57. Larson R.A. et al. A five-drug remission induction regimen with intensive consolidation for adults with ALL // Blood. 1995. Vol. 85, № 8. P. 2025–2037.
  58. Scavino H.F., George J.N., Sears D.A. Remission induction in adult acute lymphocytic leukemia. Use of vincristine and prednisone alone. // Cancer. 1976. Vol. 38, № 2. P. 672–677.
  59. Gottlieb A.J. et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. // Blood. 1984. Vol. 64, № 1. P. 267–274.
  60. Nagura E. et al. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. // Cancer Chemother. Pharmacol. 1994. Vol. 33, № 5. P. 359–365.
  61. Thomas D.A. et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia // Cancer. 2006. Vol. 106, № 7. P. 1569–1580.
  62. Goldstone A.H. et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALLXII/ECOG E2993) // Blood. 2008. Vol. 111, № 4. P. 1827–1833.
  63. Барях Е.А. et al. Лейкоз/лимфома Беркитта: клинические особенности, диагностические критерии, терапевтическая тактика // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2010. Vol. 3, № 2. P. 138–143.
  64. Malagola M., Papayannidis C., Baccarani M. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives // Annals of Hematology. Springer Verlag, 2016. Vol. 95, № 5. P. 681–693.
  65. Pfeifer H. et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia // Leukemia. 2013. Vol. 27, № 6. P. 1254–1262.
  66. Паровичникова Е.Н. et al. Острые Ph-негативные лимфобластные лейкозы взрослых: факторы риска при использовании протокола ОЛЛ-2009 // Терапевтический архив. 2016. Vol. 88, № 7. P. 15–24.
  67. Borowitz M.J. et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children’s Oncology Group study. // Leukemia. 2003. Vol. 17, № 8. P. 1566–1572.
  68. Eckert C. et al. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia-Long-term results of trial ALL-REZ BFM P95/96 // Eur. J. Cancer. 2013. Vol. 49, № 6. P. 1346–1355.
  69. Beldjord K. et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia // Blood. American Society of Hematology, 2014. Vol. 123, № 24. P. 3739–3749.
  70. Bassan R. et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). // Blood. 2009. Vol. 113, № 18. P. 4153–4162.
  71. Ribera J.M. et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial // J. Clin. Oncol. American Society of Clinical Oncology, 2014. Vol. 32, № 15. P. 1595–1604.
  72. Flohr T. et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. // Leukemia. 2008. Vol. 22, № 4. P. 771–782.
  73. Topp M.S. et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia // J. Clin. Oncol. American Society of Clinical Oncology, 2014. Vol. 32, № 36. P. 4134–4140.
  74. Литвинов Дмитрий Витальевич, Карелин Александр Федорович, Романова Ксения Игоревна, Румянцева Юлия Васильевна, Карачунский Александр Исаакович ЛЕЧЕНИЕ ОСТРОГО ЛИМФОБЛАСТНОГО ЛЕЙКОЗА У ДЕТЕЙ: СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ И НЕРЕШЕННЫЕ ПРОБЛЕМЫ // Доктор.Ру. 2015. №10 (111).
  75. Hoelzer D. et al. Acute lymphoblastic leukemia. // Hematol. Am. Soc. Hematol. Educ. Progr. 2002. P. 162–192.
  76. Huguet F. et al. Pediatric-inspired therapy in adults with philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study // J. Clin. Oncol. 2009. Vol. 27, № 6. P. 911–918.
  77. Gökbuget N. et al. Treatment of Adult ALL According to Protocols of the German Multicenter Study Group for Adult ALL (GMALL) // Acute Leukemias. Springer Berlin Heidelberg, 2007. P. 167–176.
  78. Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (ALL) – Adult // The University of Texas MD Anderson Cancer Center. 2019.
  79. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia // New England Journal of Medicine. 2006. Vol. 354, № 2. P. 166–178.
  80. Inaba H., Pui C.-H. Glucocorticoid use in acute lymphoblastic leukemia: comparison of prednisone and dexamethasone // Lancet Oncol. 2012. Vol. 11, № 11. P. 1096–1106.
  81. Sawalha Y., Advani A.S. Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. // Int. J. Hematol. Oncol. 2018. Vol. 7, № 1. P. IJH02.
  82. Wetzler M. et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: Results of CALGB study 10001 (alliance) // Haematologica. 2014. Vol. 99, № 1. P. 111–115.
  83. Гаврилина О.А. et al. Результаты ретроспективного многоцентрового исследования терапии Ph-позитивных острых лимфобластных лейкозов по протоколам российской исследовательской группы // Гематология и трансфузиология. 2017. Vol. 62, № 4. P. 172–180.
  84. Blackburn L.M. et al. Leukostasis: Management to prevent crisis in acute leukemia // Clin. J. Oncol. Nurs. Oncology Nursing Society, 2017. Vol. 21, № 6. P. E267–E271.
  85. Ali R. et al. Maternal and fetal outcomes in pregnancy complicated with acute leukemia: a single institutional experience with 10 pregnancies at 16 years. // Leuk. Res. 2003. Vol. 27, № 5. P. 381–385.
  86. Троицкая В.В. et al. Лечение острых лимфобластных лейкозов у беременных по протоколу ОЛЛ-2009 // Гематология и трансфузиология. 2018. Vol. 63, № 3. P. 209–230.
  87. Vlijm-Kievit A. et al. Acute lymphoblastic leukemia during the third trimester of pregnancy // Leuk. Lymphoma. 2018. Vol. 59, № 5. P. 1274–1276.
  88. Mainor C.B. et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy // J. Oncol. Pharm. Pract. SAGE Publications Ltd, 2016. Vol. 22, № 2. P. 374–377.
  89. Kemp M.W. et al. The clinical use of corticosteroids in pregnancy // Human Reproduction Update. Oxford University Press, 2016. Vol. 22, № 2. P. 240–259.
  90. Zaidi A. et al. Management of Concurrent Pregnancy and Acute Lymphoblastic Malignancy in Teenaged Patients: Two Illustrative Cases and Review of the Literature // J. Adolesc. Young Adult Oncol. Mary Ann Liebert Inc, 2014. Vol. 3, № 4. P. 160–175.
  91. Van Veen J.J., Nokes T.J., Makris M. The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals // British Journal of Haematology. John Wiley & Sons, Ltd, 2010. Vol. 148, № 1. P. 15–25.
  92. Преждевременные роды. Клинические рекомендации (протокол лечения). 2013. P. 20.
  93. Rizzari C. et al. Outcome of very late relapse in children with acute lymphoblastic leukemia // Haematologica. 2004. Vol. 89, № 4. P. 427–434.
  94. Zhao J. et al. Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy. // Int. J. Gen. Med. 2015. Vol. 8. P. 211–214.
  95. Jaime-Perez J.C. et al. Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: A single-center experience // Leuk. Lymphoma. Taylor and Francis Ltd, 2015. Vol. 56, № 9. P. 2524–2528.
  96. Luskin M.R. et al. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma // British Journal of Haematology. Blackwell Publishing Ltd, 2016. Vol. 174, № 2. P. 332–334.
  97. Peirs S. et al. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. // Leukemia. 2017. Vol. 31, № 10. P. 2037–2047.
  98. Ribera J.M. et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the programa Español de tratamiento en hematología pediatric-based protocol ALL-96 // J. Clin. Oncol. 2008. Vol. 26, № 11. P. 1843–1849.
  99. Snyder D.S. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. // Biol. Blood Marrow Transplant. 2000. Vol. 6, № 6. P. 597–603.
  100. Fielding A.K. et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study // Blood. 2007. Vol. 109, № 3. P. 944–950.
  101. Oriol A. et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. // Haematologica. 2010. Vol. 95, № 4. P. 589–596.
  102. Lau T.K.H., Yip C.H.W., Yeo W. State of the Art Antiemetic Therapy for Cancer Patients. // Curr. Oncol. Rep. 2016. Vol. 18, № 1. P. 2.
  103. Alkayed K., Al Hmood A., Madanat F. Prognostic effect of blood transfusion in children with acute lymphoblastic leukemia. // Blood Res. 2013. Vol. 48, № 2. P. 133–138.
  104. Blumberg N. et al. Platelet transfusion and survival in adults with acute leukemia // Leukemia. Nature Publishing Group, 2008. Vol. 22, № 3. P. 631–635.
  105. Farrell K. et al. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events // Leuk. Lymphoma. Taylor and Francis Ltd, 2016. Vol. 57, № 11. P. 2568–2574.
  106. Бокерия Л.А., Затевахин И.И., Кириенко А.И. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). // Флебология. 2015. Vol. 4, № 2. P. 3–52.
  107. Ueda M. et al. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. // Blood Rev. 2018. Vol. 32, № 2. P. 106–115.
  108. Bates J.S., Buie L.W., Woodis C.B. Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy // Pharmacotherapy. 2011. Vol. 31, № 11. P. 1092–1110.
  109. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.
  110. Geludkova O. et al. Quality of life in children with acute lymphoblastic leukemia (ALL) in remission // Med. Pediatr. Oncol. 2001. Vol. 37, № 3. P. Abstract p168.
  111. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, № 5 Suppl 1. P. S88-94.
  112. Чернуха Г.Е. Аномальные маточные кровотечения репродуктивного периода // Гинекология: национальное руководство. Краткое издание. Под ред. Г.М. Савельевой. Г.Т. Сухих, В.Н. Серова, В.Е. Радзинского, И.Б. Манухина. М.: ГЭОТАР-Медиа, 2020. P. 170–175.
  113. Доброхотова Ю.Э. et al. Аномальные маточные кровотечения: алгоритмы ведения, методы терапии // РМЖ. Мать и дитя. 2020. Vol. 3, № 1. P. 55–60.
  114. Мамонов В.Е. Неотложная нейрохирургия внутричерепных кровоизлияний у пациентов гематологического стационара // Гематология и трансфузиология. 2020. Vol. 65, № S1. P. 174–175.
  115. Narum S., Westergren T., Klemp M. Corticosteroids and risk of gastrointestinal bleeding: A systematic review and meta-analysis // BMJ Open. BMJ Publishing Group, 2014. Vol. 4, № 5.
  116. Conn H.O., Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. // J. Intern. Med. J Intern Med, 1994. Vol. 236, № 6. P. 619–632.
  117. Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression // Gastroenterology. Gastroenterology, 1990. Vol. 99, № 2. P. 345–351.
  118. Ивашкин В.Т. et al. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Vol. 30, № 1. P. 49–70.
  119. Scally B. et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials // Lancet Gastroenterol. Hepatol. Elsevier Ltd, 2018. Vol. 3, № 4. P. 231–241.
  120. Hu Z.-H. et al. Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials // Saudi J. Gastroenterol. Medknow Publications, 2017. Vol. 23, № 1. P. 11.
  121. Poynard T., Lemaire M., Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer // Eur. J. Gastroenterol. Hepatol. 1995. Vol. 7, № 7. P. 661–665.
  122. Охмат В.А. et al. Спектр и этиология инфекционных осложнений у больных острыми миелоидными лейкозами на этапах индукции и консолидации ремиссии // Гематология и трансфузиология. 2017. Vol. 62, № 1. P. 9–15.
  123. Клясова Г.А. et al. Возбудители сепсиса у иммунокомпрометированных больных: структура и проблемы антибиотикорезистентности (результаты многоцентрового исследования) // Гематология и трансфузиология. 2007. Vol. 52, № 1. P. 11–18.
  124. Клясова Г.А., Охмат В.А. Антимикробная терапия // Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под редакцией Савченко В.Г. Москва: Практика, 2018. P. 1067–1114.
  125. Maertens J. et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL 32009 update // Bone Marrow Transplant. Nature Publishing Group, 2011. Vol. 46, № 5. P. 709–718.
  126. Kollef M.H. et al. Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial // Lancet Infect. Dis. Lancet Publishing Group, 2019. Vol. 19, № 12. P. 1299–1311.
  127. Averbuch D. et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011) // Haematologica. Ferrata Storti Foundation, 2013. Vol. 98, № 12. P. 1836–1847.
  128. Debast S.B. et al. European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection // Clin. Microbiol. Infect. Blackwell Publishing Ltd, 2014. Vol. 20, № S2. P. 1–26.
  129. Arendrup M.C. et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections // Clin. Microbiol. Infect. Blackwell Publishing Ltd, 2014. Vol. 20, № S3. P. 76–98.
  130. Tissot F. et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients // Haematologica. Ferrata Storti Foundation, 2017. Vol. 102, № 3. P. 433–444.
  131. Мальчикова А.О., Клясова Г.А. Формирование биопленок у изолятов Candida spp, выделенных из гемокультуры от больных с опухолями системы крови // Клиническая микробиология и антимикробная химиотерапия. 2018. Vol. 20, № 2. P. 126–130.
  132. Ullmann A.J. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline // Clin. Microbiol. Infect. Elsevier B.V., 2018. Vol. 24. P. e1–e38.
  133. Cornely O.A. et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium // The Lancet Infectious Diseases. Lancet Publishing Group, 2019. Vol. 19, № 12. P. e405–e421.
  134. Tortorano A.M. et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others // Clin. Microbiol. Infect. Blackwell Publishing Ltd, 2014. Vol. 20, № S3. P. 27–46.
  135. Maschmeyer G. et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients // J. Antimicrob. Chemother. J Antimicrob Chemother, 2016. Vol. 71, № 9. P. 2405–2413.
  136. Styczynski J. et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: Guidelines from the Second European Conference on Infections in Leukemia // Bone Marrow Transplant. Bone Marrow Transplant, 2009. Vol. 43, № 10. P. 757–770.
  137. Ljungman P. et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT // Bone Marrow Transplant. Bone Marrow Transplant, 2008. Vol. 42, № 4. P. 227–240.
  138. Maertens J. et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients // Journal of Antimicrobial Chemotherapy. Oxford University Press, 2016. Vol. 71, № 9. P. 1–8.
  139. Протоколы трансплантации аллогенных гепомоэтических стволовых клеток. Под ред. В.Г. Савченко. М.: Практика, 2020. 320 p.
  140. Welte K. et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor // Proc. Natl. Acad. Sci. U. S. A. Proc Natl Acad Sci U S A, 1985. Vol. 82, № 5. P. 1526–1530.
  141. Krause D.S. et al. CD34: Structure, biology, and clinical utility // Blood. American Society of Hematology, 1996. Vol. 87, № 1. P. 1–13.
  142. Giralt S. et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations // Biology of Blood and Marrow Transplantation. Elsevier, 2014. Vol. 20, № 3. P. 295–308.
  143. Stiff P.J. et al. Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma // Biol. Blood Marrow Transplant. Biol Blood Marrow Transplant, 2011. Vol. 17, № 8. P. 1146–1153.
  144. Passos-Coelho J.L. et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte- macrophage colony-stimulating factor mobilization // J. Clin. Oncol. American Society of Clinical Oncology, 1995. Vol. 13, № 3. P. 705–714.
  145. Hohaus S. et al. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. // Exp. Hematol. 1993. Vol. 21, № 4. P. 508–514.
  146. Покровская О.С., Менделеева Л.П., Гальцева И.В., Варламова Е.Ю., Капланская И.Б., Воробьев И.А., Грецов Е.М., Калинин Н.Н., Варламова С.В., Клясова Г.А., Тихонова Л.Ю. С.В.Г. Мобилизация гемопоэтических клеток крови у больных миеломной болезнью // Проблемы гематологии и переливания. 2003. P. 55–56.
  147. Olivieri A. et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: An analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo // Bone Marrow Transplant. Bone Marrow Transplant, 2012. Vol. 47, № 3. P. 342–351.
  148. Yang B.B., Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim // Clinical Pharmacokinetics. Clin Pharmacokinet, 2011. Vol. 50, № 5. P. 295–306.
  149. Costa L.J. et al. Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: Efficacy and cost analysis // Transfusion. Transfusion, 2012. Vol. 52, № 11. P. 2375–2381.
  150. Dale D.C. et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim // Supportive Care in Cancer. Springer Verlag, 2018. Vol. 26, № 1. P. 7–20.
  151. Smith T.J. et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update // J. Clin. Oncol. American Society of Clinical Oncology, 2015. Vol. 33, № 28. P. 3199–3212.
  152. Bilgin Y.M., De Greef G.E. Plerixafor for stem cell mobilization: The current status // Current Opinion in Hematology. Lippincott Williams and Wilkins, 2016. Vol. 23, № 1. P. 67–71.
  153. Бабенецкая Д.В., Моторин Д.В., Петров А.В., Алексеева Ю.А. З.А.Ю. Мобилизация гемопоэтических стволовых клеток препаратами циклофосфамид и цитарабин в сочетании с колониестимулирующим фактором у больных множественной миеломой, кандидатов для проведения трансплантации аутологичных гемопоэтических стволовых клеток // Гематология и трансфузиология. 2017. № 62(4). P. 180-187.
  154. Покровская О.С. Кроветворная ткань и стромальное микроокружение в процессе интенсивной терапии и мобилизации гемопоэтических стволовых клеток у больных множественной миеломой: Автореф. дис.канд.мед.наук. 2011. Vol. 153. 29 p.
  155. Афанасьева О.И., Воинов В.А. Г.Ю.С. Экстракорпоральная гемокоррекция: терминология, языковые соответствия. СПб, 2016. P. 7–15.
  156. Ikeda K. et al. Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study // Transfusion Medicine Reviews. W.B. Saunders, 2018. Vol. 32, № 3. P. 186–194.
  157. Sutherland D.R. et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry // Journal of Hematotherapy and Stem Cell Research. J Hematother, 1996. Vol. 5, № 3. P. 213–226.
  158. Паровичникова Е.Н.. и др. Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Том 1. Москва: Практика, 2024. 928 p.
  159. Lanas A., Chan F.K.L. Peptic ulcer disease. // Lancet (London, England). Lancet, 2017. Vol. 390, № 10094. P. 613–624.
  160. Auner H.W. et al. Infectious complications after autologous hematopoietic stem cell transplantation: Comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma // Ann. Hematol. Ann Hematol, 2002. Vol. 81, № 7. P. 374–377.
  161. Gil L., Styczynski J., Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: Risk factors analysis and outcome // Infection. Infection, 2007. Vol. 35, № 6. P. 421–427.
  162. Eleutherakis-Papaiakovou E. et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: Results of a single institution, randomized phase 2 trial // Am. J. Hematol. Am J Hematol, 2010. Vol. 85, № 11. P. 863–867.
  163. Neumann S. et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DG // Annals of Hematology. Ann Hematol, 2013. Vol. 92, № 4. P. 433–442.
  164. Moghnieh R. et al. Bacteraemia post-autologous haematopoietic stem cell transplantation in the absence of antibacterial prophylaxis: a decade’s experience from Lebanon // Infection. Urban und Vogel GmbH, 2018. Vol. 46, № 6.
  165. Клясова Г.А. et al. Эмпирическая антимикробная терапия у больных острыми лейкозами: итоги многоцентрового исследования // Терапевтический архив. 1998. Vol. 70, № 7. P. 15–21.
  166.  Olga Aleshina (Gavrilina),  Ekaterina Kotova,  Galina Isinova,  Zalina Fidarova,  Irina Lukianova,  Vera Troitskaya,  Irina Galtseva,  Tatiana Obukhova,  Valentina Dvirnik,  Chabaeva Julia,  Sergey Kulikov,  Elena Parovichnikova. THE FIRST RESULTS OF THE RALL-2016M PROTOCOL: “MRD-STATUS” BASED TARGET THERAPY FOR PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULT PATIENTS. EHA Library. Aleshina (Gavrilina) O. 06/13/2024; 419826; P1739
  167. Сытов А.В., Лейдерман И.Н., Ломидзе С.В., Нехаев И.В. Х.А.Ж.. Практические рекомендации по нутритивной поддержке онкологических больных // RUSSCO. 2017. P. 524–532.
  168. Virizuela J.A. et al. Nutritional support and parenteral nutrition in cancer patients: an expert consensus report // Clin. Transl. Oncol. Springer-Verlag Italia s.r.l., 2018. Vol. 20, № 5. P. 619–629.
  169. Бесова Н.С., Борисова Т.Н., Ларионова В.Б., Лейдерман И.Н., Обухова О.А., Попова Т.С., Салтанов А.И., Сельчук В.Ю., Снеговой А.В., Ткачев С.И., Тюляндин С.А. Ш.А.И. Клинические рекомендации по нутритивной поддержке при химиотерапии и/или лучевой терапии. 2014.
  170. Arends J. et al. ESPEN guidelines on nutrition in cancer patients // Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, № 1. P. 11–48.
  171. Camblor-Álvarez M. et al. Soporte nutricional y nutrición parenteral en el paciente oncológico: informe de consenso de un grupo de expertos // Nutr. Hosp. ARAN Ediciones, 2018. Vol. 35, № 1.
  172. Baiu I., Spain D.A. Parenteral Nutrition // JAMA - Journal of the American Medical Association. American Medical Association, 2019. Vol. 321, № 21. P. 2142.
  173. Криволапов Ю.А. Технические аспекты выполнения трепанобиопсий костного мозга. Клиническая онкогематология 2014; 7:290—295 // Клиническая онкогематология. 2014. Vol. 7. P. 290–295.
  174. Wang J. et al. Diagnostic utility of bilateral bone marrow examination: Significance of morphologic and ancillary technique study in malignancy // Cancer. Cancer, 2002. Vol. 94, № 5. P. 1522–1531.
  175. Fong B., Van Bendegon J.M. Lumbar puncture. Neurologic and neurosurgical procedures // Rechman, E.F., Simon, R.R., eds. Emergency Medicine Procedures. New York: McGraw-Hill, 2004. P. 859–880.
  176. Троицкая В.В. et al. Протокол индукционной фазы лечения острых лейкозов, протекающих с гиперлейкоцитозом // Алгоритмы диагностики и протоколы лечения заболеваний системы крови. НМИЦ Гематологии. Под ред. В.Г. Савченко. Практика, 2018. P. 731–752.
  177. Porcu P. et al. Leukocytoreduction for acute leukemia // Ther. Apher. Ther Apher, 2002. Vol. 6, № 1. P. 15–23.
  178. Szczepiorkowski Z.M. et al. Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the apheresis applications committee of the American Society for Apheresis // Journal of Clinical Apheresis. Wiley-Liss Inc., 2010. Vol. 25, № 3. P. 83–177.
  179. Ganzel C. et al. Hyperleukocytosis, leukostasis and leukapheresis: Practice management // Blood Rev. Blood Rev, 2012. Vol. 26, № 3. P. 117–122.
  180. SPIRIN M., GALSTYAN G., DROKOV M. Central venous access in lymphoma patients (pts) with superior vena cava syndrome (SVCS) // INTENSIVE CARE Med. Exp. 2019. Vol. 7, № Suppl. 3:001341. P. 388–389.
  181. Pluschnig U. et al. Extravasation emergencies: state-of-the-art management and progress in clinical research. // Memo. Springer, 2016. Vol. 9, № 4. P. 226–230.
  182. Zeidler K. et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. // Transfusion. 2011. Vol. 51, № 11. P. 2269–2276.
  183. Zerati A.E. et al. Totally implantable venous catheters : history , implantation technique and complications. // J Vasc Bras. 2017. Vol. 16, № 2. P. 128–139.
  184. Gow K.W., Tapper D., Hickman R.O. Between the lines: The 50th anniversary of long-term central venous catheters // Am. J. Surg. Elsevier Ltd, 2017. Vol. 213, № 5. P. 837–848.
  185. Yeral M. et al. Tunnelled central venous catheter-related problems in the early phase of haematopoietic stem cell transplantation and effects on transplant outcome. // Turkish J. Haematol. Off. J. Turkish Soc. Haematol. Galenos Yayinevi, 2015. Vol. 32, № 1. P. 51–57.
  186. Maki D.G., Kluger D.M., Crnich C.J. The Risk of Bloodstream Infection in Adults With Different Intravascular Devices: A Systematic Review of 200 Published Prospective Studies // Mayo Clin. Proc. Elsevier, 2006. Vol. 81, № 9. P. 1159–1171.
  187. Hamilton H. Central Venous Catheters / ed. Bodenham A.R. Oxford, UK: Wiley-Blackwell, 2009.
  188. Biffi R. Introduction and Overview of PICC History // Peripherally Inserted Central Venous Catheters. Milano: Springer Milan, 2014. P. 1–6.
  189. Linenberger M.L. Catheter-related thrombosis: risks, diagnosis, and management. // J. Natl. Compr. Canc. Netw. 2006. Vol. 4, № 9. P. 889–901.
  190. Lee A.Y.Y., Kamphuisen P.W. Epidemiology and prevention of catheter-related thrombosis in patients with cancer // J. Thromb. Haemost. 2012. № 10. P. 1491–1499.
  191. Цепенщинков Л.., Лядов В.К. Периферически имплантируемый центральный венозный катетер: обзор литераутры. // Клиническая онкогематология. 2014. Vol. 7, № 2. P. 220–228.
  192. Linder L.E. et al. Material thrombogenicity in central venous catheterization: a comparison between soft, antebrachial catheters of silicone elastomer and polyurethane. // JPEN. J. Parenter. Enteral Nutr. 1984. Vol. 8, № 4. P. 399–406.
  193. Watters V.A., Grant J.P. Use of Electrocardiogram to Position Right Atrial Catheters During Surgery // Ann. Surg. Vol. 225, № 2. P. 165–171.
  194. Taal M.W., Chesterton L.J., McIntyre C.W. Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis // Nephrol. Dial. Transplant. Oxford University Press, 2004. Vol. 19, № 6. P. 1542–1545.
  195. Lobato E.B. et al. Cross-sectional area of the right and left internal jugular veins. // J. Cardiothorac. Vasc. Anesth. 1999. Vol. 13, № 2. P. 136–138.
  196. Червонцева А.М. Повреждение сосудистого эндотелия в процессе лечения острых миелоидных лейкозов. 2008.
  197. Багирова Н.С. Инфекции, связанные с внутрисосудистыми устройствами: терминология, диагностика, профилактика и терапия // Злокачественные опухоли. 2014. № 3. P. 164–171.
  198. Bannon M.P., Heller S.F., Rivera M. Anatomic considerations for central venous cannulation. // Risk Manag. Healthc. Policy. Dove Press, 2011. Vol. 4. P. 27–39.
  199. Milling T.J. et al. Randomized, controlled clinical trial of point-of-care limited ultrasonography assistance of central venous cannulation: The Third Sonography Outcomes Assessment Program (SOAP-3) Trial* // Crit. Care Med. 2005. Vol. 33, № 8. P. 1764–1769.
  200. Алешина О.А., Котова Е. С., и соавторы. Результаты пилотной фазы одноцентрового проспективного исследования "ОЛЛ-2016м" лечения взрослых пациентлов Ph-негативными острыми лимфобластными лейкозами. Гематология и трансфузиология. 2024. Т69. №S2.С23.
  201. Галстян Г.М. НАРУШЕНИЯ ГЕМОСТАЗА, ОБУСЛОВЛЕННЫЕ ДЕФИЦИТОМ ВИТАМИН К-ЗАВИСИМЫХ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ — ПАТОГЕНЕЗ, СПОСОБЫ КОРРЕКЦИИ И РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ. // Гематология и трансфузиология. 2012. Vol. 27, № 2. P. 7–21.
  202. Roze des Ordons A.L. et al. Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: A case-control study // BMC Cancer. 2010. Vol. 10. P. 516.
  203. Schellongowski P. et al. Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience // Haematologica. 2011. Vol. 96, № 2. P. 231–237.
  204. Lengliné E. et al. Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure // Leuk. Lymphoma. Leuk Lymphoma, 2012. Vol. 53, № 7. P. 1352–1359.
  205. Jackson K. et al. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit // Leuk. Lymphoma. Leuk Lymphoma, 2013. Vol. 55, № April. P. 1–8.
  206. Pohlen M. et al. Patients with acute myeloid leukemia admitted to intensive care units: Outcome analysis and risk prediction // PLoS One. Public Library of Science, 2016. Vol. 11, № 8.
  207. Halpern A.B. et al. Association of risk factors, mortality, and care costs of adults with acute myeloid leukemia with admission to the intensive care unit // JAMA Oncol. American Medical Association, 2017. Vol. 3, № 3. P. 374–381.
  208. Воробьев А.И. et al. Критические состояния при гемобластозах (типичные формы и выживаемость в условиях отделения реанимации). // Терапевтический архив. 1993. Vol. 65, № 7. P. 3–6.
  209. Галстян Г.М., Городецкий В.М. Опыт работы отделения реанимации и интенсивной терапии ФГБУ ГНЦ МЗиСР РФ // Клиническая онкогематология. 2011. Vol. 4, № 1. P. 75–78.
  210. Lamia B. et al. Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU // Intensive Care Med. Intensive Care Med, 2006. Vol. 32, № 10. P. 1560–1568.
  211. Evison J.M. et al. Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors. 2001.
  212. Silfvast T. et al. Multiple organ failure and outcome of critically ill patients with haematological malignancy // Acta Anaesthesiol. Scand. Acta Anaesthesiol Scand, 2003. Vol. 47, № 3. P. 301–306.
  213. Benoit D.D. et al. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication // Crit. Care Med. Crit Care Med, 2003. Vol. 31, № 1. P. 104–112.
  214. Medić M.G. et al. Hematologic malignancies in the medical intensive care unit – Outcomes and prognostic factors // Hematology. Maney Publishing, 2015. Vol. 20, № 5. P. 247–253.
  215. Ahmed T. et al. Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit // Leuk. Res. Elsevier Ltd, 2017. Vol. 62. P. 51–55.
  216. Wohlfarth P. et al. Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit // Ann. Hematol. Springer Verlag, 2014. Vol. 93, № 10. P. 1629–1636.
  217. Fan E., Brodie D., Slutsky A.S. Acute Respiratory Distress Syndrome // JAMA. American Medical Association, 2018. Vol. 319, № 7. P. 698.
  218. Riley D.O., Schlefman J.M., Vitzthum Von Eckstaedt V.H.C., Morris A.L., Keng M.K., El Chaer F. Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefi t. Curr Hematol Malig Rep. 2021;16(3):314–24. doi: 10.1007/s11899-021-00638-0.
  219. Sorror M.L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. // Blood. The American Society of Hematology, 2005. Vol. 106, № 8. P. 2912–2919.
  220. Sorror M.L. et al. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study // Biol. Blood Marrow Transplant. Elsevier Inc., 2015. Vol. 21, № 8. P. 1479–1487.
  221. June C.H., O’Connor R.S., Kawalekar O.U., et al. CAR T cell immunotherapy for human cancer. Vol. 359, Science. American Association for the Advancement of Science; 2018. p. 1361–5. DOI:10.1126/science.aar6711.
  222. Maude S.L., Laetsch T.W., Buechner J., et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439–48. DOI:10.1056/nejmoa1709866.
  223. Shah B.D., Ghobadi A., Oluwole O.O., et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502. DOI:10.1016/S0140-6736(21)01222-8.
  224. Cerrano M., Bonifacio V., Olivi M., et al. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. Haematologica. 2022; 107(4):996-999.
  225. Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study. Journal of Clinical Oncology. 2022; 40(16):10001-100001.
  226. Sokolov AN, Parovichnikova EN, Troitskaya VV et al. BCR/ABL, IKZF deletions and FLT3-ITD as the targets for relapsed/refractory B-cell acute lymphoblastic leukemia treatment: Blinatumomab combined with Tyrosine kinase inhibitors and ATRA. Cell Th er Transplant. 2020; 9(1): 38-46
  227. Chen X, Huang J, Xu N, et al. A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia. Cancer. 2022;128(11):2138–2147.
  228. Клиническая апробация метода терапии "Иммунотерапия биспецифичным анти-CD19/CD3 моноклональным антителом в комбинации с ингибиторами тирозинкиназ у больных с рефрактерным течением острого лимфобластного лейкоза с целью снижения токсичности лечения и увеличения его эффективности" №2018-30-8.
  229. Aumann S, Shaulov A, Haran A, Gross Even-Zohar N, Vainstein V, Nachmias B. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia. Int J Mol Sci. 2022;23(18):10957.
  230. Gibson, A., Trabal, A., McCall, D., Khazal, S., Toepfer, L., Bell, D. H., et al.. Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancers (Basel). 2022; 14, 150.
  231. Kołodrubiec, J., Kozłowska, M., Irga-Jaworska, N., Sędek, Ł., Pastorczak, A., Trelińska, J., et al. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review. Leuk. Res. 2022; 121, 106925.
  232. Pullarkat, V. A., Lacayo, N. J., Jabbour, E., Rubnitz, J. E., Bajel, A., Laetsch, T. W., et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021; 11, 1440–1453.
  233. Richard-Carpentier, G., Jabbour, E., Short, N. J., Rausch, C. R., Savoy, J. M., Bose, P., et al. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin. Lymphoma, Myeloma Leuk. 2020; 20, 212–218.
  234. Tran, T.H., Tasian, S.K. Treatment of Ph-Like Acute Lymphoblastic Leukemia. In: Litzow, M.R., Raetz, E.A. (eds) Clinical Management of Acute Lymphoblastic Leukemia. Springer, Cham. 2020.
  235. Wang J., Shen S., Hu B., et al. Successful use of trametinib and dasatinib combined with chemotherapy in treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report. Medicine. 2021. 100(25): e26440.
  236. Alaggio, R., Amador, C., Anagnostopoulos, I. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36, 1720–1748 (2022). https://doi.org/10.1038/s41375-022-01620-2
  237. Richard C. Harvey, Sarah K. Tasian; Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia. Blood Adv 2020; 4 (1): 218–228. doi: https://doi.org/10.1182/bloodadvances.2019000163
  238. Постановление Правительства Российской Федерации от 28.03.2024 № 384 «Об утверждении Правил обращения биомедицинских клеточных продуктов, предназначенных для исполнения индивидуального медицинского назначения биомедицинского клеточного продукта, специально произведенного для отдельного пациента непосредственно в медицинской организации, в которой применяется данный биомедицинский клеточный продукт»
  239. Гаврилина О.А., Галстян Г.М., Щекина А.Е., Котова Е.С., Масчан М.А., Троицкая В.В., Королева Д.А., Звонков Е.Е., Фидарова З.Т., Васильева В.А., Паровичникова Е.Н. Терапия Т-клетками с химерным антигенным рецептором взрослых больных В-клеточными лимфопролиферативными заболеваниями. Гематология и трансфузиология. 2022;67(1):8-28. https://doi.org/10.35754/0234-5730-2022-67-1-8-28
  240. Сопроводительная терапия при лечении заболеваний системы крови. Практическое руководство / под ред. Е. Н. Паровичниковой, Г. М. Галстяна. М.: Практика, 2024. 512 с.
  241. National Comprehensive Cancer Network (NCCN) Guidelines for Acute Lymphoblastic Leukemia from Version 1.2024. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
  242. Eckert C, Parker C, Moorman AV, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021 Jul;151:175-189.
  243. Jabbour EJ, Haddad FG, Short NJ, et al. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 2024;143:417-421.
  244. Han-Yu Cao, Lu-Lu Chen, Chao-Ling Wan, et al. Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial. Blood 2023; 142 (Supplement 1): 1501.
  245. Xie J, Liu S, Zhou M, Wang Y, He H, Xiao P, Hu S, Lu J. Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children. Front Pediatr. 2023 Aug 4;11:1187607. doi: 10.3389/fped.2023.1187607. PMID: 37601130; PMCID: PMC10437063.
  246. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell
  247. Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Pignon JM, Braun T, Marolleau JP, Cahn JY, Chalandon Y, Lhéritier V, Beldjord K, Béné MC, Ifrah N, Dombret H; for GRAALL. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Sep 15;375(11):1044-53. doi: 10.1056/NEJMoa1605085. PMID: 27626518.
  248. Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J Clin Oncol. 2020 Aug 1;38(22):2519-2529. doi: 10.1200/JCO.20.00303.
  249. Гаврилина О.А., Зарубина К.И., Исинова Г.А., Троицкая В.В., Фидарова З.Т., Дроков М.Ю., Кузьмина Л.А., Бондаренко С.Н., Лапин В.А., Капланов К.Д., Гришунина М.Е., Гришунина М.Е., Паровичникова Е.Н., Савченко В.Г. РЕЗУЛЬТАТЫ ТЕРАПИИ ВЗРОСЛЫХ БОЛЬНЫХ PH-ПОЗИТИВНЫМИ ОСТРЫМИ ЛИМФОБЛАСТНЫМИ ЛЕЙКОЗАМИ: ДАННЫЕ РОССИЙСКОЙ ИССЛЕДОВАТЕЛЬСКОЙ ГРУППЫ ПО ИЗУЧЕНИЮ ОЛЛ (RALL). Гематология и трансфузиология. 2020. Т. 65. № S1. С. 129.
  250. Паровичникова Е.Н., Алешина О.А., Троицкая В.В., Чабаева Ю.А., Соколов А.Н., Исинова Г.А., Котова Е.С., Ахмерзаева З.Х., Клясова Г.А., Гальцева И.В., Давыдова Ю.О., Кузьмина Л.А., Бондаренко С.Н., Баранова О.Ю., Антипова А.С., Самойлова О.С., Гришунина М.Е., Капланов К.Д., Капорская Т.С., Константинова Т.С. и др. СРАВНЕНИЕ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ ВЗРОСЛЫХ БОЛЬНЫХ ОСТРЫМИ PH-НЕГАТИВНЫМИ ЛИМФОБЛАСТНЫМИ ЛЕЙКОЗАМИ ПО ПРОТОКОЛАМ РОССИЙСКИХ МНОГОЦЕНТРОВЫХ ИССЛЕДОВАНИЙ "ОЛЛ-2009" И "ОЛЛ-2016". Гематология и трансфузиология. 2022. Т. 67. № 4. С. 460-477.
  251. Iacoangeli M, Roselli R, Pagano L, Leone G, Marra R, Pompucci A, Trignani R, Scerrati M. Intrathecal chemotherapy for treatment of overt meningeal leukemia: comparison between intraventricular and traditional intralumbar route. Ann Oncol. 1995 Apr;6(4):377-82. doi: 10.1093/oxfordjournals.annonc.a059187.
  252. Yuk Man Cheung, Yok-Lam Kwong; Efficacy and Safety of Asciminib in Chinese Patients with Philadelphia Chromosome(Ph)-Positive Leukaemias. Blood 2023; 142 (Supplement 1): 6383. doi: https://doi.org/10.1182/blood-2023-185578
  253. Паровичникова Е.Н.. и др. Беременность и заболевания системы крови. Практическое руководство. Москва: Практика, 2024. 320 с.
  254. Wassmann, Barbara et al. “Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).” Blood 108 5 (2006): 1469-77.
  255. https://www.fda.gov/media/107296/download - Package-Insert-and-Medication-Guide-KYMRIAH_1 PDF (www.fda.gov)
  256. Nikhil M Kumar, Rahul Bhargava, Neha Rastogi, et al.ALL-766 Asciminib as a Bridge to Allogenic Transplant in 3 Patients With Relapsed/Refractory Philadelphia Chromosome-positive ALL or CML Lymphoid Blast Crisis Refractory/Intolerant to Ponatinib,Clinical Lymphoma Myeloma and Leukemia,Volume 24, Supplement 1, 2024,Pages S283-S284,ISSN 2152-2650, https://doi.org/10.1016/S2152-2650(24)01138-8.
  257. Куликова, Станислава Станиславовна. Совершенствование терапии лимфобластных неходжкинских лимфом у подростков и молодых взрослых". : диссертация ... кандидата медицинских наук : 14.01.21 / Куликова Станислава Станиславовна; [Место защиты: ФГУ "Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии"].- Москва, 2011.- 104 с.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*